Cite
MLA Citation
W. Chen et al.. “Improved outcome for patients with relapsed/refractory mantle cell lymphoma (MCL) who stop ibrutinib +/− rituximab for reasons other than progression of disease.” Hematological oncology, vol. 35, n.d., p. 360. http://access.bl.uk/ark:/81055/vdc_100047467523.0x00002a